Antibiotics and Antivirals

Q1 — Sample Band 6 response (8 marks), with marking criteria

Natural selection and data: Each time a new antibiotic is introduced, it acts as a selection pressure on the bacterial population. Rare variants that carry resistance mutations — pre-existing before the antibiotic arrives — are spared, reproduce, and over successive generations dominate. Stimulus A demonstrates this pattern: penicillin resistance in S. aureus rose from 0% (1945) to 80% (1960) — within 15 years of widespread clinical introduction. Methicillin was introduced in 1960 specifically to treat penicillin-resistant infections; by 1990 MRSA already stood at 30%, rising to 42% by 2005. This pattern of sequential resistance development shows that every new antibiotic resets the selection clock but does not solve the underlying evolutionary problem. [1 mark: natural selection mechanism applied; 1 mark: specific data from Stimulus A used correctly]

Molecular mechanisms: Bacteria resist antibiotics via several molecular mechanisms. First, enzymatic inactivation: beta-lactamase enzymes produced by penicillin-resistant Staphylococcus cleave the beta-lactam ring structure of penicillins before they can inhibit cell wall synthesis, rendering the drug inactive. Second, target modification: MRSA carries a mutated penicillin-binding protein (PBP2a), encoded by the mecA gene, that is structurally different from the normal PBP2 — penicillins bind PBP2a with very low affinity, so cell wall synthesis continues despite the antibiotic's presence. Both mechanisms are heritable and transferable via horizontal gene transfer (plasmids), explaining the rapid cross-species spread of resistance. [1 mark: two named molecular mechanisms with correct examples]

Commercial and prescribing factors: Stimulus B identifies two interacting crises. First, the pharmaceutical pipeline: no genuinely new antibiotic class has been introduced since 1987 — pharmaceutical companies have abandoned the antibiotic market because a successful antibiotic must be used sparingly (preserving effectiveness), which makes it commercially unprofitable. The result is that bacteria are developing resistance faster than new drugs are being developed to replace them. Second, inappropriate prescribing: 30% of Australian primary care antibiotic prescriptions are inappropriate — most commonly for viral respiratory infections. This exposes bacteria in patients' microbiomes to unnecessary selection pressure while delivering no therapeutic benefit, accelerating resistance in the community without any clinical gain. [1 mark: pipeline problem with commercial explanation; 1 mark: prescribing problem with Australian data]

Management strategies evaluated: Antibiotic stewardship programs — hospital and primary care guidelines restricting prescribing to indicated infections, reserving last-resort drugs (e.g. vancomycin), and switching to narrow-spectrum agents where possible — directly reduce selection pressure. The Stimulus A data showing MRSA declining from 42% (2005) to 28% (2020) is at least partly attributable to stewardship programs introduced in Australian hospitals from the early 2000s. However, stewardship is limited by compliance — patients can still pressure GPs for antibiotics, and international coordination is poor. Completing antibiotic courses reduces the chance that resistant survivors repopulate — this is effective because stopping early is one of the most significant individual drivers of resistance. The limitation is that education alone is insufficient; studies show patients frequently misunderstand or ignore advice. New drug development (including phage therapy — using bacteriophage viruses that infect and kill specific bacteria without affecting human cells) offers a long-term solution that bypasses the resistance problem. Phage therapy is highly specific (a phage that infects MRSA does not affect other bacteria), but is still largely experimental and requires bespoke matching of phage to pathogen. Agricultural reform — reducing growth-promoter antibiotic use in livestock — addresses one of the largest global drivers of resistance but faces strong economic opposition from agribusiness. [1 mark: two strategies with both effectiveness and limitations for each]

Integrative conclusion: No single strategy is sufficient because the resistance crisis has multiple independent drivers. Stewardship reduces community-level selection pressure but does nothing to develop new drugs. Completing courses helps individual treatment outcomes but is irrelevant to agricultural resistance. New drug development alone resets the clock without slowing resistance evolution. The most effective response combines all four: stewardship and prescribing reform to slow resistance accumulation now, education to ensure courses are completed, agricultural policy reform to reduce the largest volume driver, and sustained investment in new antibiotic classes and alternative approaches like phage therapy to replenish the therapeutic arsenal before existing drugs fail. The Stimulus B data — 1.27 million deaths annually, exceeding HIV/AIDS — makes the urgency clear and justifies the investment cost. [1 mark: integrative conclusion explaining why no single strategy suffices, with explicit reference to multiple drivers; 1 mark: explicitly links the AMR death toll data to justify urgency]

Marking criteria:

• 1 mark — Correctly explains how natural selection produces resistance (pre-existing variants; antibiotic as selection pressure; survival and reproduction of resistant).
• 1 mark — Uses at least one specific data point from Stimulus A to illustrate the pattern (e.g. penicillin 0%→80% in 15 years; MRSA from 2% to 42%).
• 1 mark — Names and correctly explains two distinct molecular resistance mechanisms with named examples (beta-lactamase / MRSA PBP2a / efflux pump / porin reduction / metabolic bypass).
• 1 mark — Uses Stimulus B to explain the commercial pipeline problem: lack of financial incentive → no new antibiotic classes since 1987.
• 1 mark — Uses Stimulus B to explain the prescribing problem: inappropriate prescription for viral infections increases resistance without benefit.
• 1 mark — Evaluates two management strategies, including for each both its effectiveness and a genuine limitation.
• 1 mark — Reaches an integrative conclusion: explains why multiple strategies are necessary because different strategies address different drivers, and no single strategy is sufficient alone.
• 1 mark — Explicitly uses the mortality/burden data (either from lesson or Stimulus B) to support the urgency of the conclusion.

Q2 — Source critique (7 marks), with marking criteria

Overall judgment: The source is largely unreliable as a source of health information. It contains at least four significant biological errors that could lead readers to misuse medications, hold false expectations, or misunderstand how their immune system works. One element — that viruses develop resistance to antivirals — is approximately correct but is incompletely explained and misleadingly presented as analogous to bacterial resistance when the mechanisms differ.

Error 1 — "Antivirals work the same way as antibiotics by disrupting metabolism." This is wrong. Antibiotics target bacterial-specific structures (peptidoglycan cell walls, 70S ribosomes, bacterial DNA gyrase, folate synthesis) that are absent in human cells. Antivirals target virus-specific enzymes and processes — neuraminidase (influenza), reverse transcriptase (HIV), viral protease (HIV, COVID-19 Paxlovid), or viral RNA polymerase — that have no equivalent in the antibiotic target list. The mechanisms are fundamentally different: antibiotics exploit differences between prokaryote and eukaryote biology; antivirals exploit the few viral-specific enzymes not shared with the host cell. The shared concept is selective toxicity — but the targets are entirely different. [1 mark: error identified and correctly explained with mechanism]

Error 2 — "Tamiflu directly destroys virus particles already in the body." This is wrong. Oseltamivir (Tamiflu) is a neuraminidase inhibitor — it inhibits the enzyme influenza uses to release new virions from infected cells. It does not destroy existing viral particles. Antivirals generally do not "kill" viruses in the way antibiotics kill bacteria; they inhibit a step in the replication cycle, preventing new virus from being produced and spread, while the immune system clears existing infection. Starting Tamiflu early is effective precisely because it reduces the rate of viral replication before peak viral load — not because it destroys existing virions. [1 mark: error identified and correctly explained]

Error 3 — "Viruses develop resistance to antivirals just like bacteria do to antibiotics." This is approximately correct in outcome (both pathogens can develop drug resistance) but the mechanism comparison is misleading. Viral resistance arises through rapid mutation of the viral genome (especially RNA viruses like HIV and influenza, which have error-prone RNA polymerases), not through horizontal gene transfer of resistance plasmids as commonly occurs with bacteria. Additionally, the analogy implies the process is identical, which obscures why HIV requires three-drug HAART (to prevent resistance through triple-targeting) rather than a single drug — a clinical nuance the source omits. [1 mark: partially correct element identified; explanation of key mechanistic difference between viral and bacterial resistance]

Error 4 — "Once someone has taken an antiviral, their immune system becomes resistant permanently — antivirals and vaccines serve exactly the same purpose." This is wrong in two ways. First, antivirals do not produce immune memory — they suppress viral replication during an acute infection but do not stimulate the adaptive immune response in the way vaccines do. A patient who takes Tamiflu for influenza does not acquire lasting immunity to that strain. Second, vaccines work by presenting antigens to the immune system to stimulate the production of antigen-specific memory B and T cells, providing lasting (though not always permanent) protection against future infection. Antivirals treat an active infection; vaccines prevent infection from establishing or becoming severe in the first place. They are mechanistically, pharmacologically and clinically distinct. [1 mark: error identified with correct explanation of both antiviral and vaccine mechanisms; 1 mark: clear distinction between treatment and prevention/immune memory]

Overall reliability: The source scores poorly as a health information resource. Three of its four main claims are outright wrong and the fourth is partially misleading. A reader who accepted this source at face value might expect Tamiflu to clear existing viral particles (leading to false reassurance about timing of treatment), assume that taking antivirals provides permanent immunity (leading them to skip vaccination), or misconstrue antiviral resistance as identical to antibiotic resistance (affecting their understanding of HIV treatment). The source does correctly identify that antivirals and antibiotics have different effectiveness profiles and that resistance is a challenge for both drug classes — but this core of truth is embedded in so much error that it does not rescue the source's reliability. [1 mark: overall evaluative judgment citing specific consequences of the errors for patient understanding]

Marking criteria:

• 1 mark — Identifies Error 1 (antivirals ≠ antibiotics in mechanism) and correctly explains the difference in targets (bacterial structures vs viral-specific enzymes).
• 1 mark — Identifies Error 2 (Tamiflu does not destroy virions; it inhibits neuraminidase/virion release) and explains the correct mechanism.
• 1 mark — Engages correctly with Error 3 (resistance is approximately correct but mechanism analogies are misleading; explains how viral and bacterial resistance differ, e.g. RNA polymerase error rate vs plasmid HGT).
• 1 mark — Identifies Error 4 (antivirals do not create immune memory) and explains the correct mechanism of antiviral action during acute infection.
• 1 mark — Explains the correct mechanism of vaccine action (antigen stimulates adaptive immune memory via B/T cells) and explicitly distinguishes it from antiviral action.
• 1 mark — Acknowledges the one approximately correct element (viral resistance is a real phenomenon) with a nuanced explanation of why the analogy to antibiotic resistance is still misleading.
• 1 mark — Reaches an explicit overall reliability judgment: identifies the source as unreliable, gives at least one concrete consequence for patient understanding, and demonstrates a balanced evaluation (not simply listing errors).